6/#455 Management of immune-related adverse events in patients with solid tumors treated with dostarlimab in the garnet study. (4th December 2022)

• Record Type: Journal Article
• Authors: Banerjee, Susana; Andre, Thierry; Berton, Dominique; Oaknin, Ana; Moreno, Victor; Trigo, José; Curigliano, Giuseppe; Tinker, Anna; Boni, Valentina; Barretina-Ginesta, Maria Pilar; Pikiel, Joanna; Pothuri, Bhavana; Mirza, Mansoor; Panovcova, Petra; Duan, Tao; Dabrowski, Christine; Zografos, Eleftherios; Veneris, Jennifer
• Is Part Of: International journal of gynecological cancer. Volume 32(2022)Supplement 3
• Page Start: A27
• Page End: A28
• Publication Date: 2022-12-04
• Subjects: Generative organs, Female -- Cancer -- Periodicals; 616.99465
• DOI: 10.1136/ijgc-2022-igcs.50
• Languages: English
• ISSNs: 1048-891X

Abstract

Abstract : Objectives: Dostarlimab is an approved programmed death 1 (PD-1) inhibitor. PD-1 therapy can lead to immune-related adverse events (irAEs). Here we report on the management of irAEs across multiple tumor types evaluated in GARNET. Methods: GARNET is a multicenter, open-label, single-arm phase 1 study with dose expansion in multiple tumor types: dMMR solid tumors, mismatch repair proficient EC, non-small cell lung cancer, and platinum-resistant ovarian cancer. Patients received 500 mg of dostarlimab intravenously Q3W for 4 cycles, then 1000 mg Q6W until disease progression, discontinuation, or withdrawal. Results: At this third interim analysis of GARNET, the safety population included 605 patients. irAEs were experienced by 32.2%, with 10.1% of patients experiencing grade ≥3 irAEs ( table 1 ). Few, 5.5%, discontinued treatment because of an irAE. No irAEs led to death. Of patients experiencing irAEs, 64.6% were treated with immune modulatory medications (IMMs; referring to steroids, immune suppressant, and/or thyroid therapy); 58.7% of these patients experienced resolution. Average time to resolution was 69 days. For the 35.4% of patients not treated with IMMs, 56.5% experienced a resolution. Average time to resolution was 67 days. The most common irAEs were hypothyroidism (7.6%; 45 of 46 [97.8%] patients treated with thyroid therapy) and arthralgia (5.6%; 8 of 34 [23.5%] patients treated with steroids). Conclusions: Across all tumor types evaluated in GARNET, 32.2% of patients experienced irAEs, 68.7% of whom experienced grade 2 events. 58.7% of patients experienced resolution of irAEs upon treatment with an IMM. Overall discontinuation due to irAEs was low.